Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

96 results
Display

Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer In Vitro and In Vivo

Lin CL, Tsai ML, Chen Yh, Liu WN, Lin CY, Hsu KW, Huang CY, Chang YJ, Wei PL, Chen SH, Huang LC, Lee CH

Thyroid cancer is the most common endocrine malignancy. Patients with well-differentiated thyroid cancers, such as papillary and follicular cancers, have a favorable prognosis. However, poorly differentiated thyroid cancers, such as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia

Xu X, Lu Q, Wang Z, Cai P, Zeng Z, Zhang L, Wang M, Ma L, Ruan C, Chen S

Platelet-derived growth factor receptor beta (PDGFRB) rearrangements play an important role in the pathogenesis of eosinophilia-associated myeloid/lymphoid neoplasms. Up to now, more than 70 PDGFRB fusions have been identified. Here,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case Report of Multiple Capillary Hemangioma in a Chronic Myeloid Leukemia Patient Taking Tyrosine Kinase Inhibitors

Byun HJ, Jang D, Lee J, Oh SJ, Lim Y, Park JH, Lee JH, Lee DY

A capillary hemangioma is a vascular tumor with small capillary sized vascular channel. Multiple capillary hemangioma in relation with drugs have been rarely reported. Here in, we report a case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of imatinib mesylate in a dog with meningoencephalitis of unknown etiology

Song JH, Jung DI

A 4-year-old, female, Maltese dog with bilateral hind limb ataxia was brought to Gyeongsang National University Animal Medical Center (GAMC). Based on the previous medical and imaging records, the patient...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D’Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C

Background Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2

Zhang H, Yi J, Yoon D, Ryoo Z, Lee I, Kim M

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is one of the leading causes of cancer-related deaths worldwide. Imatinib and GNF-5 are breakpoint cluster region-Abelson murine leukemia...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice

Hong YH, Kim SJ, Kim SK, Lee SC, Jun JH, Jee BC, Kim SH

Objective: We investigated the impact of tyrosine kinase inhibitor (imatinib or dasatinib) coadministration with cyclophosphamide (Cp) on preantral follicle development in an in vitro mouse model. Methods: Seventy-three female BDF1 mice...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient

Kim HJ, Park JY, Kim BJ, Kim JG, Kim HS, Park JM

Although high-risk gastrointestinal stromal tumors (GISTs) frequently recur, even after a complete resection and imatinib therapy, local recurrence at the suture line after complete resection is rare. The present case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Influencing Imatinib-Induced Hepatotoxicity

Han JM, Yee J, Cho YS, Gwak HS

Purpose Although imatinib-induced hepatotoxicity may aggravate the patient’s clinical condition and alter the treatment plan, the underlying mechanism of and factors influencing imatinibinduced hepatotoxicity have rarely been investigated. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neuroprotective potential of imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43

Wang J, Bai T, Wang N, Li H, Guo X

The present study was aimed to explore the neuroprotective role of imatinib in global ischemia-reperfusion-induced cerebral injury along with possible mechanisms. Global ischemia was induced in mice by bilateral carotid...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor

Kang MK, Lee HJ, Choi JH

Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy

Bedewy AM, Elmaghraby SM, Kandil NS

BACKGROUND: ATP-binding cassette transporters are important in the mechanism of multidrug resistance. ABCB1 displays a high affinity for imatinib. BMI1 is a polycomb group protein thought to be overexpressed in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib

Kim DS, Lee S, Choi CW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

Yim E, An HJ, Cho U, Kim Y, Kim SH, Choi YG, Shim BY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-growth Effects of Imatinib and GNF5 via Regulation of Skp2 in Human Hepatocellular Carcinoma Cells

Kim SH, Kim MO, Kim KR

BACKGROUND: Human hepatocellular carcinoma (HCC) is a common liver tumor and the main cause of cancer-related death. Tyrosine kinase inhibitors, such as imatinib and GNF5 which were developed to treat...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Composition of Pharmaceutical Expenditure in National Health Insurance and Implications for Reasonable Spending

Lee HJ

BACKGROUND: The proportion of pharmaceutical expenditure out of total health-care expenditure in South Korea is high. In 2016, 25.7% of national health insurance (NHI) spending was for pharmaceuticals. Given the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor

Park EH, Kim JI, Cheung DY, Park SH

Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21

Zhou X, Yuan P, Liu Q, Liu Z

Imatinib resistance has become a major clinical problem for chronic myeloid leukemia. The aim of the present study was to investigate the involvement of MEG3, a lncRNA, in imatinib resistance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRB presenting as congestive heart failure and hypereosinophilia

Kwon JW, Kwon JH, Her AY

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK

PURPOSE: The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr